http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 03:22:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO) has signed a binding offer to acquire 100% of the share capital of Etherna Immunotherapies NV at a total enterprise value of €30 million, to be settled through a combination of cash and shares.</p> <p>Etherna, a Belgian biotechnology company, develops mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP standards. The deal would combine Etherna's mRNA and LNP capabilities with Valerio's single-domain antibody targeting and conjugation technologies.</p> <p>The transaction is subject to foreign direct investment clearance in Belgium, finalization of transaction documentation, completion of financing secured by subscription undertakings from existing Valerio shareholders, and http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+bids+%E2%82%AC30M+for+Etherna+Immunotherapies/26715648.html Wed, 01 Jul 2026 03:22:21 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html <ul class="bwlistdisc"> <li> The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs </li> </ul><ul class="bwlistdisc"> <li> The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline </li> </ul><ul class="bwlistdisc"> <li> The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Binding+Offer+for+the+Proposed+Acquisition+of+Etherna+Immunotherapies%2C+Creating+a+Global+Leader+in+Targeted+RNA+Medicines/26715647.html Wed, 01 Jul 2026 03:22:00 -0400 A.01025616 A.14767858 A.17839596 A.50216954 ALONX ALVIO O.00046810 O.00367392 O.15112568 O.19829730 O.57271643